AR051296A1 - Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-(4-((metilamino)metil)fenil)-1,3,4,5-tetrahidro-6h-azepino(5,4,3-cd)indol-6-ona - Google Patents
Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-(4-((metilamino)metil)fenil)-1,3,4,5-tetrahidro-6h-azepino(5,4,3-cd)indol-6-onaInfo
- Publication number
- AR051296A1 AR051296A1 ARP050103934A ARP050103934A AR051296A1 AR 051296 A1 AR051296 A1 AR 051296A1 AR P050103934 A ARP050103934 A AR P050103934A AR P050103934 A ARP050103934 A AR P050103934A AR 051296 A1 AR051296 A1 AR 051296A1
- Authority
- AR
- Argentina
- Prior art keywords
- azepino
- tetrahydro
- fluoro
- phenyl
- methyl
- Prior art date
Links
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 title 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 229910019142 PO4 Inorganic materials 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title 1
- 239000010452 phosphate Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61245904P | 2004-09-22 | 2004-09-22 | |
| US67929605P | 2005-05-09 | 2005-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR051296A1 true AR051296A1 (es) | 2007-01-03 |
Family
ID=35526956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103934A AR051296A1 (es) | 2004-09-22 | 2005-09-20 | Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-(4-((metilamino)metil)fenil)-1,3,4,5-tetrahidro-6h-azepino(5,4,3-cd)indol-6-ona |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7268126B2 (enExample) |
| EP (1) | EP1799685B1 (enExample) |
| JP (1) | JP2008513436A (enExample) |
| KR (1) | KR100853601B1 (enExample) |
| AR (1) | AR051296A1 (enExample) |
| AT (1) | ATE551345T1 (enExample) |
| AU (1) | AU2005286191B2 (enExample) |
| BR (1) | BRPI0516766A (enExample) |
| CA (1) | CA2581025C (enExample) |
| ES (1) | ES2382950T3 (enExample) |
| IL (1) | IL181463A (enExample) |
| MX (1) | MX2007002461A (enExample) |
| NO (1) | NO337938B1 (enExample) |
| NZ (1) | NZ554659A (enExample) |
| RU (1) | RU2355691C2 (enExample) |
| TW (1) | TWI365188B (enExample) |
| WO (1) | WO2006033007A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1611137A1 (en) * | 2003-03-31 | 2006-01-04 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| SG164368A1 (en) * | 2005-07-18 | 2010-09-29 | Bipar Sciences Inc | Treatment of cancer |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| AU2007292306A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof |
| AU2007292387A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| WO2008114114A2 (en) * | 2007-03-16 | 2008-09-25 | Pfizer Products Inc. | Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition |
| NZ586123A (en) * | 2007-11-12 | 2012-12-21 | Bipar Sciences Inc | Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors |
| KR20100102609A (ko) * | 2007-11-12 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법 |
| CA2708157A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| KR20100112192A (ko) * | 2008-02-04 | 2010-10-18 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ－매개된 질병을 진단 및 치료하는 방법 |
| KR20170095402A (ko) | 2009-11-09 | 2017-08-22 | 알러간, 인코포레이티드 | 모발 성장을 촉진하기 위한 조성물 및 방법 |
| CA3024216C (en) | 2010-02-12 | 2021-03-30 | Pfizer Inc. | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
| WO2011141909A2 (en) | 2010-05-10 | 2011-11-17 | Radikal Therapeutics Inc. | Lipoic acid and nitroxide derivatives and uses thereof |
| AU2014216112B2 (en) | 2013-02-15 | 2019-02-21 | Allergan, Inc. | Sustained drug delivery implant |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| RS67356B1 (sr) | 2014-08-22 | 2025-11-28 | Pharma& Schweiz Gmbh | Tablete rukapariba visoke doze |
| JP6457696B2 (ja) | 2015-07-23 | 2019-01-23 | アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ | 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用 |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| US10875870B2 (en) | 2017-01-24 | 2020-12-29 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib and of rucaparib salts |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| CN110997068B (zh) | 2017-05-24 | 2022-12-06 | 宾夕法尼亚大学董事会 | 用于成像和放射疗法的经放射标记的荧光parp抑制剂 |
| MX2020004545A (es) * | 2017-11-03 | 2020-08-03 | Sandoz Ag | Sal cristralina de un inhibidor triciclico de poli(adp-ribosa)-polimerasa. |
| US10933069B2 (en) | 2018-01-05 | 2021-03-02 | Cybrexa 1, Inc. | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues |
| US10442813B2 (en) | 2018-01-30 | 2019-10-15 | RK Pharma Solutions LLC | Polymorphs of rucaparib camsylate and methods of making same |
| WO2019175132A1 (en) | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
| PH12022550037A1 (en) | 2019-07-10 | 2023-04-12 | Cybrexa 3 Inc | Peptide conjugates of microtubule-targeting agents as therapeutics |
| EP3997093A1 (en) | 2019-07-10 | 2022-05-18 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4100125A1 (en) | 2020-02-03 | 2022-12-14 | Sandoz AG | Polymorph of rucaparib mesylate |
| ES3014370T3 (en) | 2020-04-28 | 2025-04-22 | Rhizen Pharmaceuticals Ag | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
| EP4182318B1 (en) | 2020-07-14 | 2025-08-27 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib salts |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| AU2022255809A1 (en) | 2021-04-08 | 2023-10-26 | Incozen Therapeutics Pvt. Ltd. | Inhibitors of poly(adp-ribose) polymerase |
| EP4463232A1 (en) | 2022-01-11 | 2024-11-20 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib tosylate |
| WO2024261243A1 (en) | 2023-06-21 | 2024-12-26 | Hemispherian As | Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US649554A (en) * | 1899-04-08 | 1900-05-15 | Ferdinand Schwedtmann | Electric switch. |
| GB8806449D0 (en) * | 1988-03-18 | 1988-04-20 | Janssen Pharmaceutica Nv | Antiviral hexahydroimiazo(1 4)benzodiazepin-2-ones |
| PL210415B1 (pl) * | 1999-01-11 | 2012-01-31 | Agouron Pharma | Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu |
| EP1611137A1 (en) * | 2003-03-31 | 2006-01-04 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| ATE454893T1 (de) * | 2003-07-25 | 2010-01-15 | Cancer Rec Tech Ltd | Tricyclische parp-hemmer |
-
2005
- 2005-09-12 MX MX2007002461A patent/MX2007002461A/es active IP Right Grant
- 2005-09-12 WO PCT/IB2005/002941 patent/WO2006033007A2/en not_active Ceased
- 2005-09-12 CA CA2581025A patent/CA2581025C/en not_active Expired - Lifetime
- 2005-09-12 AT AT05799991T patent/ATE551345T1/de active
- 2005-09-12 BR BRPI0516766-3A patent/BRPI0516766A/pt not_active Application Discontinuation
- 2005-09-12 EP EP05799991A patent/EP1799685B1/en not_active Expired - Lifetime
- 2005-09-12 KR KR1020077006422A patent/KR100853601B1/ko not_active Expired - Fee Related
- 2005-09-12 RU RU2007110026/04A patent/RU2355691C2/ru active
- 2005-09-12 NZ NZ554659A patent/NZ554659A/en not_active IP Right Cessation
- 2005-09-12 JP JP2007531869A patent/JP2008513436A/ja active Pending
- 2005-09-12 AU AU2005286191A patent/AU2005286191B2/en not_active Ceased
- 2005-09-12 ES ES05799991T patent/ES2382950T3/es not_active Expired - Lifetime
- 2005-09-20 AR ARP050103934A patent/AR051296A1/es unknown
- 2005-09-21 US US11/233,835 patent/US7268126B2/en not_active Expired - Lifetime
- 2005-09-21 TW TW094132634A patent/TWI365188B/zh not_active IP Right Cessation
-
2007
- 2007-02-16 NO NO20070920A patent/NO337938B1/no unknown
- 2007-02-20 IL IL181463A patent/IL181463A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| NZ554659A (en) | 2010-08-27 |
| ES2382950T3 (es) | 2012-06-14 |
| EP1799685A2 (en) | 2007-06-27 |
| EP1799685B1 (en) | 2012-03-28 |
| WO2006033007A3 (en) | 2006-11-02 |
| KR100853601B1 (ko) | 2008-08-22 |
| US20060100198A1 (en) | 2006-05-11 |
| CA2581025C (en) | 2011-06-07 |
| TWI365188B (en) | 2012-06-01 |
| AU2005286191A1 (en) | 2006-03-30 |
| MX2007002461A (es) | 2008-03-13 |
| TW200613305A (en) | 2006-05-01 |
| ATE551345T1 (de) | 2012-04-15 |
| RU2007110026A (ru) | 2008-10-27 |
| CA2581025A1 (en) | 2006-03-30 |
| US7268126B2 (en) | 2007-09-11 |
| HK1116483A1 (en) | 2008-12-24 |
| AU2005286191B2 (en) | 2011-11-17 |
| JP2008513436A (ja) | 2008-05-01 |
| IL181463A (en) | 2012-02-29 |
| IL181463A0 (en) | 2007-07-04 |
| RU2355691C2 (ru) | 2009-05-20 |
| BRPI0516766A (pt) | 2008-09-16 |
| WO2006033007A2 (en) | 2006-03-30 |
| NO20070920L (no) | 2007-03-15 |
| NO337938B1 (no) | 2016-07-11 |
| KR20070089121A (ko) | 2007-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051296A1 (es) | Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-(4-((metilamino)metil)fenil)-1,3,4,5-tetrahidro-6h-azepino(5,4,3-cd)indol-6-ona | |
| MX343383B (es) | Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3, 4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona. | |
| MX377802B (es) | Metodos y composiciones para trastornos del sueño y otros trastornos. | |
| BRPI0917119A2 (pt) | composto, composição farmacêutica, métodos para inibir a poli(adp-ribose) polimerase em um paciente, para tratar uma doença, uso de um composto, e, artigo de fabricação. | |
| WO2008003007A3 (en) | Compositions and methods for treating parasitic infections | |
| CL2009000954A1 (es) | Compuestos derivados de 2-imino-3-metil pirrolo pirimidinona,inhibidores de bace-1; composicion farmaceutica; y su uso para tratar, prevenir y/o retardar el inicio de una patologia de beta-amiloide seleccionada de enfermedad de alzheimer, enfermedad de parkinson, perdida de la memoria, sindrome de down, entre otras. | |
| EA201001256A1 (ru) | Производные диазаспиро[5.5]ундекана в качестве антагонистов мускариновых рецепторов и агонистов бета-адренорецепторов для применения в лечении легочных расстройств | |
| LTPA2016034I1 (lt) | Brutono tirozinkinazės inhibitoriai | |
| WO2006076620A3 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
| DK1812440T3 (da) | Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser | |
| CR10211A (es) | Compuestos de tiazol y métodos de uso | |
| NO20084853L (no) | Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni | |
| CL2007001918A1 (es) | Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras. | |
| CL2009000380A1 (es) | Compuestos derivados de heterociclos, moduladores de beta-amiloide; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la enfermedad de alzheimer, angioplastia cerebral amiloide, demencia multiinfarto, sindrome de down, entre otras. | |
| DE602007007985D1 (de) | Als inhibitoren von proteinkinasen geeignete aminopyrimidine | |
| ATE497961T1 (de) | Als proteinkinaseinhibitoren geeignete verbindungen | |
| WO2010093727A8 (en) | Quinazolinones as prolyl hydroxylase inhibitors | |
| NI200800175A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de abuso y adicción de sustancias. | |
| UY29766A1 (es) | Formas cristalinas delta y épsilon de mesilato de imatinib | |
| WO2007120760A3 (en) | Thiophene-carboxamides useful as inhibitors of protein kinases | |
| CL2008002689A1 (es) | Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia. | |
| WO2007076161A3 (en) | Compounds with therapeutic activity | |
| WO2006053049A3 (en) | Herbal composition phy906 and its use in chemotherapy | |
| CL2009001137A1 (es) | Compuestos derivados de cicloheptanocarboniloxi-1-azonia-biciclo[2.2.2]-octano, moduladores de receptores muscarinicos; composiciones farmaceuticas; proceso de preparacion de dicha composicion; y uso en el tratamiento de una enfermedad pulmonar obstructiva cronica. | |
| DE602006017574D1 (de) | Als protein-kinase-inhibitoren nutzbare benzimidazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |